By David M. Haas Lambert
Pick up one of the hemp THC seltzers now sitting in grocery coolers and you’re holding a pharmaceutical drug-delivery system in consumer packaging. I mean that as a formulation claim, not a rhetorical one. And once you see how it’s built, the chairside implications for a dental practice follow directly.
The problem the formulators had to solve
THC is lipophilic. It doesn’t dissolve in water. Drop the oil into a can and it separates, and whatever a patient absorbs comes slowly and incompletely. For a poorly soluble drug, absorption is limited by how fast the compound can dissolve, and dissolution rate scales with the surface area exposed to fluid. That’s first-year pharmaceutics, and it’s the wall every insoluble drug runs into.
So the beverage makers borrowed the solution the drug industry has used for decades on insoluble compounds: reduce particle size. Shrink an oil droplet from the micron scale down to nanometers and you multiply its total surface area enormously. More surface, faster dissolution, better absorption. At the nanoscale the droplets also behave as if water-compatible and can begin absorbing across the oral and gastric mucosa before the liver ever sees them.
That’s a nanoemulsion, and it’s genuinely sophisticated formulation work. It’s the same class of technique used to make marginally soluble pharmaceuticals bioavailable. Applied here, it turns an oily intoxicant that would barely absorb into a fast, efficient delivery vehicle. (Labroots; ACS Laboratory)
What that does to the pharmacokinetics
Compare it to the edible everyone already understands. An oil-based gummy clears the gut, gets emulsified by bile, absorbs, then runs first-pass hepatic metabolism, which converts most of the delta-9 into 11-hydroxy-THC. Onset is 45 to 90 minutes, the high is long and heavy, and bioavailability is poor, commonly put at 4 to 20%.
The nanoemulsion beverage inverts most of that. Reported onset falls to roughly 15 to 30 minutes, bioavailability climbs several-fold, and because some absorption bypasses the liver, more parent delta-9 reaches circulation and the 11-hydroxy ratio drops. The felt experience is faster, shorter, and more alcohol-like, which is exactly the market it was engineered for. (Applied Pharmacognosy)
One honest caveat, because it’s my standard and it should be yours. Those onset and bioavailability figures lean heavily on formulator claims and animal studies. Controlled human pharmacokinetic data on the specific commercial hemp beverages is thin. Treat the exact numbers as directional. The direction, nano beverages absorbing faster and more completely than oil edibles, is well established.
Why this lands in your operatory
The ADA has reported that roughly half of dentists say they’ve treated a patient who was high. The fast-onset drink makes that harder to manage, for a specific reason: timing.
A patient who drinks one of these in the parking lot 20 minutes before you seat them can be at peak effect at the moment you inject. Cannabis raises heart rate somewhere between 20 and 100%, peaking 10 to 30 minutes after use, and epinephrine in your local anesthetic adds to that load. The dental literature is not shy about it. Epinephrine can prolong and intensify cannabis-induced tachycardia, and in a recent user that combination is a genuine cardiovascular concern, not a theoretical one. Regular users also tend to need higher and less predictable doses of sedatives, and acute intoxication raises the odds of anxiety, dysphoria, and paranoid reactions in the chair. (Decisions in Dentistry; DOCS Education; ADA)
Then there’s the disclosure gap, which the formulation creates on purpose. The product looks like a hard seltzer and feels like a drink, so patients don’t file it under “cannabis.” Ask “do you use marijuana?” and a patient who had a THC seltzer at lunch can answer no and believe it. The packaging and the alcohol-like experience work against your screening question. If your intake asks about cannabis in the abstract, it will miss the beverage.
A practical fix costs nothing: ask about timing and form, not identity. “Have you had any cannabis, edible, or THC drink today, and when?” The when is what changes your epinephrine and sedation decisions, and the explicit mention of a drink catches the patient who wouldn’t otherwise count it.
The larger point, and the sunset
Step back and the object in the cooler is a deliberately engineered drug-delivery system sold as a soft drink, with none of the oversight a drug product carries. The technology was developed for licensed, tested, dose-controlled cannabis markets, then ported to exploit the federal hemp loophole and placed on an open shelf, for a while with no age limit at all.
That loophole closes on November 12, 2026, when a new federal definition caps finished products at 0.4 mg of total THC per container and the intoxicating versions largely come off these shelves. (National Law Review)
The formulation technology does not close. Nanoemulsion migrates to whatever’s legal next, CBD and functional beverages, or the dispensary channel in legal states. The delivery system outlives this particular loophole, which means the pharmacokinetics you now understand will keep showing up in your patients in one product or another. Worth knowing regardless of what the label says.
Educational content, current as of August 2026. Not legal or clinical advice for a specific case. Verify current regulations and screening protocols for your jurisdiction and practice.